Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6100791 | Journal of Crohn's and Colitis | 2009 | 7 Pages |
Abstract
The results indicate that the addition of 1Â g topical mesalazine results in significant cost-savings and moderate quality of life improvements. We have also shown that irrespective of which treatment modality is used in steroid-refractory patients (eg, infliximab, azathioprine, ciclosporine) that topical mesalazine is cost-saving.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mark P. Connolly, Sandy K. Nielsen, Craig J. Currie, Philippe Marteau, Chris S.J. Probert, Simon P.L. Travis,